Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FGFR1 V561M |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR1 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR1 V561M | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | FIIN-1 | Preclinical - Biochemical | Actionable | In a preclinical study, FIIN-1 inhibited Fgfr1 autophosphorylation in a human transformed embryonic kidney cell line harboring FGFR1 V561M mutation in culture (PMID: 20338520). | 20338520 |
FGFR1 V561M | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | PRN1371 | Preclinical - Cell culture | Actionable | In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR1 V561M in culture (PMID: 28978721). | 28978721 |
FGFR1 V561M | lung non-small cell carcinoma | resistant | FGFR1 Inhibitor | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, non-small cell lung cancer cells expressing FGFR1 V561M demonstrated resistance to AZD4547 in culture (PMID: 30257990). | 30257990 |
FGFR1 V561M | Advanced Solid Tumor | predicted - resistant | FGFR Inhibitor (Pan) | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 V561M demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 34114373). | 34114373 |
FGFR1 V561M | Advanced Solid Tumor | predicted - resistant | FGFR Inhibitor (Pan) | Ponatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 V561M demonstrated insensitivity to Iclusig (ponatinib) in culture (PMID: 34114373). | 34114373 |
FGFR1 V561M | Advanced Solid Tumor | sensitive | FGFR1 Inhibitor | Olverembatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Olverembatinib (HQP1351) treatment inhibited cell growth and Fgfr1 phosphorylation and downstream pathway activation in cells expressing FGFR1 V561M in culture and inhibited tumor growth in cell line xenograft models, with a tumor growth inhibition of 49.8% (PMID: 34114373). | 34114373 |
FGFR1 V561M | Advanced Solid Tumor | predicted - resistant | FGFR Inhibitor (Pan) | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Lytgobi (futibatinib) failed to inhibit cell growth and Fgfr1 downstream signaling in cells expressing FGFR1 V561M in culture (PMID: 34114373). | 34114373 |
FGFR1 V561M | Advanced Solid Tumor | predicted - resistant | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Truseltiq (infigratinib) failed to inhibit cell growth and Fgfr1 downstream signaling in cells expressing FGFR1 V561M in culture (PMID: 34114373). | 34114373 |
FGFR1 V561M | Advanced Solid Tumor | predicted - resistant | FGFR1 Inhibitor | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Pemazyre (pemigatinib) failed to inhibit cell growth and Fgfr1 downstream signaling in cells expressing FGFR1 V561M in culture (PMID: 34114373). | 34114373 |
FGFR1 V561M | Advanced Solid Tumor | predicted - sensitive | FGFR1 Inhibitor | 3D185 | Preclinical - Biochemical | Actionable | In a preclinical study, 3D185 inhibited kinase activity of FGFR1 V561M in an in vitro assay (PMID: 31438996). | 31438996 |
FGFR1 V561M | Advanced Solid Tumor | predicted - resistant | FGFR1 Inhibitor | Pemigatinib | Preclinical - Biochemical | Actionable | In a preclinical study, a cell line expressing FGFR1 V561M was resistant to Pemazyre (pemigatinib) in a kinase assay (PMID: 36698015). | 36698015 |